Inhibikase Therapeutics, Inc.
IKT
$1.84
$0.084.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 5.27M | 10.51M | 7.19M | 4.19M | 3.08M |
| Gross Profit | -5.27M | -10.51M | -7.19M | -4.19M | -3.08M |
| SG&A Expenses | 5.92M | 5.25M | 5.74M | 1.64M | 1.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -358.40K | -- | -- | -- | -- |
| Total Operating Expenses | 10.83M | 15.76M | 12.93M | 5.83M | 5.05M |
| Operating Income | -10.83M | -15.76M | -12.93M | -5.83M | -5.05M |
| Income Before Tax | -9.92M | -13.68M | -12.13M | -5.78M | -4.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.92M | -13.68M | -12.13M | -5.78M | -4.96M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.92M | -13.68M | -12.13M | -5.78M | -4.96M |
| EBIT | -10.83M | -15.76M | -12.93M | -5.83M | -5.05M |
| EBITDA | -10.81M | -15.75M | -12.92M | -5.82M | -5.04M |
| EPS Basic | -0.11 | -0.15 | -0.17 | -0.65 | -0.66 |
| Normalized Basic EPS | -0.07 | -0.10 | -0.11 | -0.41 | -0.41 |
| EPS Diluted | -0.11 | -0.15 | -0.17 | -0.65 | -0.66 |
| Normalized Diluted EPS | -0.07 | -0.10 | -0.11 | -0.41 | -0.41 |
| Average Basic Shares Outstanding | 90.01M | 89.54M | 72.07M | 8.88M | 7.54M |
| Average Diluted Shares Outstanding | 90.01M | 89.54M | 72.07M | 8.88M | 7.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |